South African study adds more evidence Omicron is less severe, only partly vaccine-resistant
COVID-19's Omicron variant continues to spread around the U.S. and the world, and the World Health Organization on Monday deemed it a "very high" global risk. But a study released Tuesday by Discovery Health, South Africa's largest health insurer, offered more evidence that the new coronavirus strain causes milder illness, even as it evades some of the protections from the Pfizer-BioNTech vaccine.
The study examined 211,000 positive COVID-19 cases, including 78,000 South Africans who contracted the Omicron variant. It found that hospital admissions are 29 percent lower among adults infected with the Omicron than in the first wave of the pandemic back in mid-2000, and those hospitalized had less serious symptoms. .
Two doses of the Pfizer vaccine, the main vaccine in South Africa, provided just 33 percent protection against infection, much lower than against previous variants, but also provided 70 percent protection against severe symptoms that lead patients to be hospitalized, down from 90 percent against Delta, The Washington Post reports. That is still "very good protection," the researchers said. Pfizer says a third booster dose raises protection back to Delta levels.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Israel, UN agree to Gaza pauses for polio vaccinations
Speed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
By Rafi Schwartz, The Week US Published
-
WHO declares mpox a global health emergency
Speed Read An outbreak of the viral disease formerly known as monkeypox continues to spread in Africa
By Rafi Schwartz, The Week US Published